Liver/Pnacreatic Neoplasms – Pubmed

CONCLUSIONS: Integration of CIRT with systemic therapy was feasible and demonstrated an acceptable safety profile without worsening liver function. This multimodal approach may represent a treatment option for selected patients with HCC, particularly in downstaging or locally advanced settings. Prospective studies are needed to validate these findings.

CONCLUSION: AKR1B10 is a useful serum marker for the diagnosis of early and AFP-negative HCC and shows potential in assessing curative resection and early recurrence.

BACKGROUND Solitary fibrous tumor of the liver (SFTL) is a rare mesenchymal neoplasm. Most patients are asymptomatic, and lesions are discovered accidentally. Lacking specific imaging manifestations, SFTL is prone to misdiagnosis, making accurate preoperative diagnosis vital for clinical treatment. Thus, multimodal imaging is indispensable for preoperative evaluation. CASE REPORT We report the case of a 55-year-old woman with an asymptomatic liver mass identified during a routine health...

Hepatocellular carcinoma (HCC) represents one of the most lethal malignancies worldwide and is characterized by profound metabolic reprogramming during its development. Paraoxonase 1 (PON1), a liver-synthesized secretory protein involved in lipid metabolism, has an incompletely defined role in cancer biology. This study aimed to systematically investigate the expression pattern, clinical features, and biological function of PON1 in HCC through an integrated approach combining data mining,...

CONCLUSIONS: While memory CD4+ T cells exist within the PDAC TME, their activity is suppressed by miRNA-associated gene dysregulation. These data suggest candidate therapeutic approaches in which targeting of miRNAs could be used to normalize immune cells and promote anti-tumor immunity.

Metabolic reprogramming is a hallmark of cancer, yet the critical drivers and mechanisms in hepatocellular carcinoma (HCC) remain incompletely understood. Through a metabolism-focused CRISPR screen, we identified phosphomevalonate kinase (PMVK), a mevalonate pathway enzyme, as a key regulator of HCC stemness and progression. PMVK directly phosphorylates the transcription factor SP1 at Thr^(355), which enhances SP1's DNA binding affinity and promotes its interaction with the master lipid...

Pancreatic cancer remains one of the most lethal malignancies worldwide, with pancreatic ductal adenocarcinoma accounting for the vast majority of cases and characterized by extensive desmoplasia, immune exclusion, and resistance to systemic therapies. Increasing evidence implicates lysosomal cathepsins as important regulators of these defining features of pancreatic tumor biology. Cathepsin-dependent proteolysis and lysosome-associated signaling pathways contribute to extracellular matrix...

Hepatocellular carcinoma is challenging to detect at an early stage, and its severity increases over time. Recently, the incidence of hepatocellular carcinoma has increased, partly due to lifestyle-related factors such as excessive alcohol intake, sedentary behavior, and diets high in fat, which contribute to the growing prevalence of fatty liver and hepatitis. Various therapeutic strategies are being explored for hepatocellular carcinoma, among which therapies targeting deubiquitinating enzymes...

MicroRNAs are small noncoding RNA molecules that regulate gene expression at the post-transcriptional level and play a key role in cancer development, progression, and response to therapy. Their relative stability in biological fluids and disease-associated expression patterns have positioned microRNAs as promising candidates for non-invasive cancer biomarkers. Liquid biopsy enables the detection of circulating and fluid-derived microRNAs in a range of biological materials, including blood,...

CONCLUSION: Global HCC ICIs trials are highly concentrated geographically and by target, with stable research progress. However, major challenges include low result translation efficiency, unbalanced target development, insufficient early/late-phase trials and uneven global collaboration. Targeted optimization is needed to promote clinical translation.

Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer and one of the leading causes of cancer-related mortality globally, with its incidence increasingly driven not only by viral hepatitis and alcohol-related etiologies but also by metabolic dysfunction-associated steatotic liver disease. Dietary intake can modify gut microbial activity and the production of microbial metabolites, which in turn may regulate hepatic immune signaling and metabolic pathways along the...

CONCLUSIONS: T2WI habitat imaging enables improved Ki-67 prediction, supporting informed therapeutic decisions in HCC.

Colorectal cancer liver metastasis (CRLM) remains a leading cause of mortality in colorectal cancer. The metastatic liver site is characterized by an immunosuppressive microenvironment enriched with inhibitory immune cells and cytokines, contributing to a poorly inflamed, "cold" tumor phenotype. The progression of CRLM is driven by aberrant activation of oncogenic signaling pathways and a dysfunctional immune landscape, marked by T cell exhaustion and the expansion of immunosuppressive cell...

In this study, novel Benzimidazole-Hydrazone derivatives (5A-5J) were synthesized and evaluated for their in vitro anticancer activities against Panc-1, SK-MEL-30, HeLa, and BEAS-2B cell lines. WST-1 cytotoxicity assays revealed that compound 5A displayed notable potency in SK-MEL-30 cells (IC(50) = 23.25 ± 1.40 μM), whereas compound 5H exhibited significant cytotoxicity in Panc-1 cells (IC(50) = 27.6 ± 1.1 μM), with minimal effects on BEAS-2B cells (> 200 μM), suggesting a favorable in vitro...

Hepatocellular carcinoma (HCC) represents the primary liver cancer among adults with diverse tissue appearance, high disease severity, and negative treatment expectancy. The molecular heterogeneity, extensive invasion, and propensity for relapse of HCC present a substantial challenge for oncologists. Hepatoma cells display deregulated genomic pathways interacting with epigenetic modifications. Epigenetic changes are crucial in HCC research, serving as potential biomarkers for tumor...

CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, CA19.9 with the current cutoff (37 U/mL) demonstrated poor performance in excluding HGD or IC and only modest value for ruling in IC. These findings suggest CA19.9 should not be used as a standalone or screening test, while its limited rule-in value may aid decision-making in patients with moderate pretest probability. Future studies should investigate whether different cutoffs and dynamic trends could improve diagnostic...

CONCLUSION: ABHD17C promotes an immunosuppressive tumor microenvironment and attenuates the anti-tumor effects of lenvatinib in HCC. Targeting ABHD17C may represent a potential strategy to enhance lenvatinib sensitivity and improve therapeutic outcomes.

CONCLUSION: This case provides pioneering clinical evidence that cadonilimab, in combination with chemotherapy, can induce profound and durable remission in MSS PCAC, challenging current paradigms of ICI resistance and supporting the further development of bispecific antibody strategies.

Background/Objectives: Patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC) are vulnerable to rapid nutritional deterioration. The clinical relevance of short-term nutritional change during the diagnostic-to-treatment interval (DTI) remains unclear. In this study, we evaluated whether a dynamic change in the Geriatric Nutritional Risk Index (ΔGNRI) during the DTI is associated with treatment tolerability, treatment continuity, and survival. Methods: This single-center...

Pancreatic cancer is one of the most lethal malignancies, characterized by difficulties in early diagnosis, limited therapeutic options, and generally poor patient prognosis. In recent years, immunotherapy has provided new opportunities for the treatment of pancreatic cancer; however, its clinical efficacy has been substantially constrained by the complex tumor microenvironment (TME) and immune evasion mechanisms. With the rapid advancement of artificial intelligence (AI) technologies, AI has...

Background and Objectives: The role of neoadjuvant or perioperative treatment in anatomically resectable pancreatic ductal adenocarcinoma (PDAC) remains intensely debated, in part because prior evidence syntheses have often pooled resectable and borderline-resectable disease. We aim to evaluate the efficacy and safety of neoadjuvant or perioperative treatment versus upfront surgery in trial-defined resectable PDAC using randomized evidence only. Materials and Methods: We performed a systematic...

Pancreatic ductal adenocarcinoma frequently metastasises to the liver, although the mechanisms underlying hepatic pre-metastatic niche formation remain unclear. Small extracellular vesicles mediate tumour-host communication and may drive hepatic microenvironment reprogramming. This study investigated the effects of pancreatic ductal adenocarcinoma-derived small extracellular vesicles on extracellular matrix remodelling and epithelial-mesenchymal transition-related plasticity in hepatic cells....

Early detection of hepatocellular carcinoma (HCC) is crucial for curative treatment, yet current screening strategies for high-risk liver cirrhosis (LC) patients lack sufficient sensitivity. This study evaluates plasma cell-free DNA(cfDNA) concentration and fragmentomics as biomarkers to improve HCC diagnosis and prognosis. Plasma samples from 39 HCC and 46 LC patients were analyzed for cfDNA concentration and fragment patterns. A multivariate logistic regression model (CMAC), integrating cfDNA...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, characterized by marked molecular heterogeneity, late-stage diagnosis, and limited therapeutic options. Emerging evidence highlights the interplay between cytoskeletal dynamics, epigenetic regulation, and oncogenic signaling pathways in hepatocarcinogenesis. Histone deacetylase 6 (HDAC6), a key regulator of cytoplasmic protein acetylation, modulates α-tubulin stability, while CTNNB1 (β-catenin) serves...

Objective: Advanced liver cancer, a highly lethal and increasingly prevalent malignancy, frequently develops sorafenib resistance, with aberrant mitochondrial dynamics and metabolism implicated in its pathogenesis. This study aimed to investigate their interplay and assess combination therapies against sorafenib-resistant liver cancer. Methods: Mitochondrial morphology was assessed using immunofluorescent staining. Besides, the mitochondrial metabolic profile was evaluated by measuring the...

Mechanisms driving immunotherapy resistance in pancreatic cancer are poorly defined. We demonstrate that programmed death-ligand 1 immune checkpoint blockade promoted immune evasion by epigenetic Tap1 (transporter associated with antigen processing 1) silencing, increasing selection of metastatic tumor variants with defective interferon-γ (IFN-γ)-inducible class I major histocompatibility complex (MHC-I) expression. Unleashing CD4 conventional T cells by regulatory T cell (T(reg) cell)...

Hepatoblastoma (HB), the most common pediatric liver cancer, exhibits marked variability in therapeutic response despite minimal genetic heterogeneity, implicating epigenetic regulation as a key driver of tumor behavior. Among these, polycomb repressor complexes (PRC) remain poorly explored as therapeutic targets. Integrative analysis of samples from patients with HB and public datasets identified BMI1, a core component of PRC1, as significantly upregulated, with high expression strongly...

Colorectal cancer liver metastasis (CRLM) remains a leading cause of cancer-related mortality, with clinical outcomes limited by biological heterogeneity and inconsistent therapeutic responses. Despite advances in systemic chemotherapy, targeted agents, immunotherapy, and liver-directed interventions, the translation of preclinical efficacy into clinical benefit remains suboptimal, highlighting the need for predictive experimental models. However, therapeutic efficacy in CRLM is highly...

Pancreatic ductal adenocarcinoma (PDAC) presents unique treatment challenges, often due to the development of anti-cancer drug resistance. Previously, we demonstrated that CRISPR-directed gene ablation disabled the master regulator gene NRF2, a transcription factor known to control drug resistance in squamous cell carcinoma tumor cells, and restored chemosensitivity. In this short study, we evaluated a broad range of CRISPR/Cas9 molecules for their capacity to elicit similar responses in PDAC...

Hepatocellular carcinoma (HCC) develops in a chronically inflamed and dysregulated liver metabolism, in which tumor progression and resistance to treatment are orchestrated by the changes in cellular metabolism and immune control. Growing evidence recognizes immunometabolic reprogramming as the two-way interaction of metabolic processes and immune cell capabilities as one of the major determinants of immune evasion and heterogeneity of treatment response in HCC. The review aims to...

Pancreatic cancer (PC) usually results in poor survival with limited treatment options. Reactive oxygen species (ROS) play a key role in the action of HDAC inhibitors. In combination with a ROS generator, it can increase sensitivity to HDAC inhibitors and also overcome resistance to HDAC inhibitors. NQO1-bioactivatable drugs are efficient ROS generators. Therefore, to reduce HDAC inhibitor resistance and enhance its anti-pancreatic cancer activity, in this study, we reported a novel NQO1/HDAC...

Background: The synchronous occurrence of hepatocellular carcinoma (HCC) and clear cell renal cell carcinoma (ccRCC) is rare and poses significant therapeutic challenges, particularly in elderly patients with comorbidities. Although both malignancies may respond to immune checkpoint inhibitors (ICIs), evidence supporting a unified immunotherapeutic approach remains limited. This report aims to describe the clinical course and outcomes of dual immune checkpoint blockade (ICB) in a patient with...

Hepatocellular carcinoma (HCC) is sustained by coordinated interactions among malignant hepatocytes, immune cells, and stromal populations that collectively drive tumor growth, immune evasion, and vascular remodeling. Using integrative single-cell transcriptomics on 93,032 cells from tumor and healthy human liver, we characterized cell-type-specific transcriptional programs underlying immunometabolic reprogramming and reconstructed the intercellular communication circuits that maintain the tumor...

CONCLUSION: Circulating miRNA-155 is markedly upregulated in HCV-related HCC and correlates strongly with disease progression. The novel HCC-miR Score represents a simple, sensitive, and noninvasive model for the early diagnosis of HCC in high-risk HCV patients.

CONCLUSION: Patients with a history of BR or EST are at a higher risk of postoperative abscess formation in the liver resection plane. Bile leakage plays a critical role in both abscess development and prolonged healing.

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide, and first-line systemic treatment has shifted toward immune checkpoint inhibitor (ICI)-based combinations. Response is heterogeneous, and mechanistic interpretation has lagged behind clinical practice, leaving open the question of why some tumors respond while others do not. This review uses the cancer immunity cycle as an HCC-specific scaffold to map where anti-tumor immunity fails-across...

Hepatocellular carcinoma (HCC) is an aggressive cancer with poor prognosis and high mortality rates. The increasing mortality associated with HCC highlights the urgent need for alternative therapeutic approaches. Natural products and their structural analogs have shown promise as novel treatment options. This study aimed to evaluate the potential therapeutic effects of the natural flavonoids apigenin and chrysin, administered individually and in combination, in an experimental HCC model....

Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) of the central nervous system is a rare mesenchymal neoplasm with a propensity for late recurrence and distant metastasis. Pancreatic metastasis from intracranial SFT/HPC is exceptionally uncommon and may mimic primary pancreatic neoplasms, particularly pancreatic neuroendocrine tumor (PanNET). We report a 52-year-old man with a documented history of recurrent intracranial SFT/HPC, historically diagnosed as hemangiopericytoma, who developed a...

Magnetic resonance imaging (MRI) plays an essential role in cancer detection and surveillance, yet complete MRI (C-MRI) protocols are lengthy, resource-intensive, and may limit access within population-level cancer care pathways. Abbreviated MRI (A-MRI) protocols have emerged as a streamlined alternative that may preserve diagnostic performance while reducing examination time, cost, and IV contrast exposure. We conducted a narrative review of studies published between 2015 and 2025 evaluating...

Isolated Locoregionally Recurrent Pancreatic Adenocarcinoma (ILRPA) accounts for 25-30% of recurrences after radical resection, yet the role of salvage radiation (RT) in this setting remains controversial due to limited data. We aimed to evaluate the impact of salvage RT on survival outcomes compared with non-salvage RT in patients with ILRPA. We retrospectively analyzed data of patients with ILRPA post-radical resection treated at our centre between 2012 and 2021. Patients were categorized into...

The DNA damage response (DDR) is critical for pancreatic ductal adenocarcinoma (PDAC) development and therapeutic responses, including to genotoxic agents. While epigenetic modulators have been shown to contribute to the DDR, how chromatin regulation dictates responses to DNA damage in PDAC remains incompletely understood. Here, we identify Class I histone deacetylases (HDACs) as critical regulators of the DDR. HDAC1/2 direct the genomic distribution of H3K27ac, ensuring sufficient BRD4 and RNA...

Background: The clinical characteristics of pancreatic acinar cell carcinoma (ACC) remain poorly defined due to its rarity. This study aimed to evaluate the morphological features and clinical outcomes of pancreatic ACC. Method: This multicenter retrospective study analyzed clinical data from seven referral hospitals. Electronic medical records were comprehensively reviewed to extract patient data. Survival outcomes were calculated from the date of pathologic confirmation of ACC. Results: Of the...

Background: Health accessibility is a key determinant of equitable cancer care. In many countries, specialized oncology services are concentrated in urban and socioeconomically advantaged regions, forcing many patients to travel long distances for treatment. Consequently, geographic and social characteristics may be impactful in determining cancer healthcare outcomes. Objective: The aim of this study was to evaluate the association between the municipal-level Social Progress Index (SPI) and...

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with few therapeutic options. Topoisomerase IIα (TOPO2α) is frequently overexpressed in PDAC and is associated with poor clinical outcomes, yet current TOPO2α-directed therapies are constrained by limited efficacy and toxicity. Barettin, a brominated indole-containing diketopiperazine isolated from the marine sponge Geodia barretti, has not previously been evaluated against PDAC-relevant targets. Here, we identify...

CONCLUSIONS: This study suggests there may be different risk factors for rarer pancreatic cancer subtypes. Differences such as younger age and more alcohol use were noteworthy in the rarer pancreatic subtypes.

In this study, small-molecule inhibitors targeting AP5Z1 were developed, and their antitumor activity against hepatocellular carcinoma (HCC) and related mechanisms were evaluated. Candidate molecules were initially screened via computer-aided virtual screening, and CCK-8 assays were performed to verify their inhibitory effects on the proliferation of HCC cells. The interactions between compounds and targets were confirmed using techniques such as docking simulations, dynamics analyses on a...

Hepatocellular carcinoma (HCC) is undergoing a profound global epidemiological shift, transitioning from viral-driven etiologies to metabolic dysfunction-associated steatotic liver disease (MASLD). This transition challenges traditional cirrhosis-centric surveillance, as a significant proportion of MASLD-HCC develops in non-cirrhotic livers. Parallel to these metabolic shifts, the gut-liver axis has emerged as a central orchestrator of hepatocarcinogenesis. This review decodes the complex...

CONCLUSIONS: Radiotherapy achieved favorable LC with acceptable toxicity across a 20-year bi-institutional experience, supporting its role as an effective local treatment modality for adrenal metastases from HCC.

Hepatocellular carcinoma (HCC) has a poor prognosis, and the clinical responses to immune checkpoint inhibitors (ICIs) remain limited. Increasing evidence suggests that gut microbiota dysbiosis plays an important role in HCC progression through the gut-liver axis. This review summarizes the mechanisms by which polysaccharide-gut microbiota interactions reshape the immunosuppressive tumor microenvironment (TME) in HCC, and discusses the translational potential and challenges of this emerging...

Liver cancer poses a serious global health burden, with China experiencing particularly high incidence and mortality rates. Treatment complexity and severe side effects often impair patients' quality of life, leading to self-perceived burden (SPB) stemming from care dependency, financial pressure, and emotional distress. This cross-sectional study of 139 patients with liver cancer explored predictors of SPB using multiple linear regression. Results showed that 97.82% of the participants...